Pakistan Medicines & Pharma IntelligenceMedicine data  •  Company portfolios  •  Price records
MedInfoBaseMedicines · Evidence · Intelligence
Home / Pharmaceutical company intelligence
Pharmaceutical company intelligence

Adamjee Pharmaceuticals (Pvt) Ltd

Pharmaceutical manufacturer · Pakistan

Database-driven profile Portfolio, price and regulatory-source intelligence derived from MedInfoBase records.
ShareSend this page
Regulatory & corporate identity

Company profile

Not yet verified
Company type
Pharmaceutical manufacturer
DRAP-linked licence identifiersShown as recorded in linked source rows; not a claim of current validity.
DML 000236 79 linked products · source seen 10 Aug 2026 View source ↗
Location intelligence

Company location

Google Maps
Exact site not yet verified

MedInfoBase will not invent a factory or office location. The map appears after a sourced address, Place ID or verified embed URL is added.

Open in Google Maps ↗ The Google Maps search link uses the company name and available city/country context; it is not presented as a verified premises pin.
Intelligence snapshot

Portfolio at a glance

Not sales data · current MedInfoBase database view
Rx79product presentations
G29generic molecules
DF7dosage-form groups
TA6therapeutic areas
PKR79current price records
REG76registration numbers
Data coverage

How complete is this profile?

Current price coverage100%
products with a current official price
Source-linked coverage100%
products linked back to a source record
Unit-price parse coverage100%
priced packs safely normalized per unit
Comparable-market coverage92%
products with at least one like-for-like comparator
Therapeutic classification100%
products assigned to a broad therapeutic area
Visual intelligence

Downloadable company intelligence charts

Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.

Shareable intelligence

Therapeutic Portfolio Mix

Shows where the company portfolio is concentrated across broad therapeutic areas.

Therapeutic Portfolio MixAdamjee Pharmaceuticals (Pvt) LtdShare of current product presentations by broad therapeutic areaMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/adamjee-pharmaceuticals-pvt-ltdGenerated 10 Aug 2026Anti-infectives44 · 56%CNS & mental health22 · 28%Pain & musculoskeletal7 · 9%Gastrointestinal & hepatology3 · 4%Respiratory & allergy2 · 3%Fluids & supportive care1 · 1%Percentages are based on current product presentations in the MedInfoBase company portfolio.

Portfolio distribution, not sales or market-share data.

Shareable intelligence

Dosage Form Portfolio

Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.

Dosage Form PortfolioAdamjee Pharmaceuticals (Pvt) LtdDistribution of current product presentations by normalized dosage formMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/adamjee-pharmaceuticals-pvt-ltdGenerated 10 Aug 202679presentationsTablet34 · 43%Injection19 · 24%Suspension14 · 18%Capsule7 · 9%Other2 · 3%Solution2 · 3%Other forms1 · 1%Dosage-form wording is normalized for intelligence display; original source wording remains preserved in product records.

Counts are product presentations, not production or sales volumes.

Shareable intelligence

Equivalent-Market Price Position

Shows whether safely comparable products are below, near or above the market median unit price.

Equivalent-Market Price PositionAdamjee Pharmaceuticals (Pvt) LtdCurrent company products compared with like-for-like equivalent medicines using normalized unit pricesMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/adamjee-pharmaceuticals-pvt-ltdGenerated 10 Aug 202673comparable productsBelow market median23 · 32%Near market median33 · 45%Above market median17 · 23%Company median price position-0.5%Lowest-price equivalents9Method: same generic + stated strength + dosage form + compatible unit basis; pack prices normalized per unit.

This is price-position intelligence, not sales, demand or market-share data.

Shareable intelligence

Closest Portfolio Competitors

Highlights other manufacturers with the greatest generic overlap with this company portfolio.

Closest Portfolio CompetitorsAdamjee Pharmaceuticals (Pvt) LtdCompanies with the largest number of shared generic medicines in the MedInfoBase databaseMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/adamjee-pharmaceuticals-pvt-ltdGenerated 10 Aug 2026M/s. Genix Pharma (Pvt) Ltd.21 shared72% overlapNeutro Pharma (Pvt.) Ltd.,21 shared72% overlapGlitz Pharma21 shared72% overlapBio-Labs(Pvt) Ltd20 shared69% overlapTrigon Pharmaceuticals (Private) Ltd20 shared69% overlapBosch Pharmaceuticals (Pvt) Ltd.19 shared66% overlapPortfolio overlap measures shared generics only; it is not a measure of market share, affiliation or sales competition.

Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.

Portfolio intelligence

Therapeutic areas

Broad portfolio view

High-level clinical areas represented by this company’s current MedInfoBase portfolio.

Anti-infectives44 products · 56%
CNS & mental health22 products · 28%
Pain & musculoskeletal7 products · 9%
Gastrointestinal & hepatology3 products · 4%
Respiratory & allergy2 products · 3%
Fluids & supportive care1 products · 1%
Pharmacological detail

Drug classes

More specific view

More specific classes derived from the canonical generic and preserved curated classifications.

Third-generation cephalosporins15 products · 19%
Antipsychotics14 products · 18%
Fluoroquinolone antibacterials9 products · 11%
Antimalarials8 products · 10%
Antiepileptics7 products · 9%
Analgesics / NSAIDs7 products · 9%
Macrolide antibacterials6 products · 8%
Proton pump inhibitors3 products · 4%
Formulation footprint

Dosage forms

Tablet34 products
Injection19 products
Suspension14 products
Capsule7 products
Other2 products
Solution2 products
Infusion1 products
How MedInfoBase classifies the portfolio

MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.

Portfolio leaders

Deepest brand families

Ranked by registered presentations · not sales
#1 ADACIPCiprofloxacin 5presentations 125 mg/5 mL, 250 mg, 250 mg/5 mL, 500 mg · Suspension, Tablet #2 ARTINEArtemether + Lumefantrine 5presentations 15 mg/5 mL + 90 mg/5 mL, 20 mg + 120 mg, 40 mg + 240 mg, 80 mg + 480 mg · Suspension, Tablet #3 IFENIbuprofen 5presentations 100 mg/5 mL, 200 mg, 200 mg/5 mL, 400 mg · Suspension, Tablet #4 RISPRisperidone 5presentations 1 mg, 1 mg/mL, 2 mg, 3 mg · Tablet, Solution #5 ADAZONECeftriaxone 4presentations 1 g, 2 g, 250 mg, 500 mg · Injection #6 ADOXIME cefotaxamineCefotaxime 3presentations 1 g, 250 mg, 500 mg · Injection
Price intelligence

Unit-price positioning vs equivalent products

Same generic + strength + form + unit basis
Below market median2332% of comparable products
Near market median33within ±5% of median
Above market median1723% of comparable products
Lowest-price equivalents9ties included
Company median price position -0.5% relative to the median unit price of like-for-like equivalent products.
Most competitively positioned examplesProducts with at least 3 market comparators
TIAPIN 200 mgQuetiapine · Tablet · 3x10's PKR 58.17/tablet-34.3% vs market median ADESUNATE 120 mgArtesunate · Injection · 1's PKR 269.24/vial/unit-33.0% vs market median ADESUNATE 30 mgArtesunate · Injection · 1's PKR 96.93/vial/unit-32.1% vs market median FEELIX 250 mgLevofloxacin · Tablet · 1x10's PKR 37.00/tablet-22.1% vs market median TYZIDOX 500 mgCeftazidime · Injection · 1's PKR 193.86/vial/unit-20.3% vs market median
How MedInfoBase calculates price position

Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.

Competitive landscape

Portfolio overlap

Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.

M/s. Genix Pharma (Pvt) Ltd.290 products · 97 generics 21shared generics Neutro Pharma (Pvt.) Ltd.,210 products · 97 generics 21shared generics Glitz Pharma166 products · 72 generics 21shared generics Bio-Labs(Pvt) Ltd234 products · 82 generics 20shared generics Trigon Pharmaceuticals (Private) Ltd115 products · 47 generics 20shared generics Bosch Pharmaceuticals (Pvt) Ltd.250 products · 73 generics 19shared generics
Regulatory & price activity

Observed database signals

Registration numbers76
Price-history records81
Products with price history2
Source records with multiple versions0
Latest MedInfoBase verification9 Aug 2026
Latest effective price date1 Jul 2026
Latest source observation10 Aug 2026

These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.

Sponsored company campaign area · advertising must be clearly disclosed
Complete company portfolio

Products and presentations

79 results
Reset
BrandGenericStrengthFormPackRegistrationOfficial priceUnit priceMarket position
RISP Risperidone 1 mg Tablet 6x3's 026693 PKR 481.99 PKR 26.78/tablet 19% above median
SAMOPHEN Paracetamol 1000 mg /100 mL IV infusion 100ml 102913 PKR 122.41 PKR 1.22/mL No comparator
SAMOPHEN Paracetamol 125 mg/5 mL Suspension 60ml 007394 PKR 62.91 PKR 1.05/mL No comparator
TIAPIN Quetiapine 100 mg Tablet 3x10's 055620 PKR 2,417.69 PKR 80.59/tablet 14% above median
TIAPIN Quetiapine 200 mg Tablet 3x10's 095135 PKR 1,745.10 PKR 58.17/tablet 34% below median
TIAPIN Quetiapine 25 mg Tablet 3x10's 055612 PKR 704.96 PKR 23.50/tablet 13% above median
TYZIDOX Ceftazidime 1000 mg Injection 1's 110327 PKR 370.21 PKR 370.21/vial/unit 19% below median
TYZIDOX Ceftazidime 500 mg Injection 1's 110326 PKR 193.86 PKR 193.86/vial/unit 20% below median
TYZIDOX Ceftazidime 250 mg Injection 1's 110325 PKR 134.62 PKR 134.62/vial/unit 16% below median
VERMIN Mebendazole 100 mg Tablet 3x10's 010176 PKR 252.25 PKR 8.41/tablet 26% above median
VERMIN Mebendazole 100 mg/5 mL Suspension 30ml 010175 PKR 83.99 PKR 2.80/mL Near median
Water for Injection Water for Injection 5 mL Injection 5ml x 100's 101065 PKR 844.66 PKR 1.69/mL 15% below median
XMOX Moxifloxacin 400 mg Tablet 5's 055613 PKR 878.82 PKR 175.76/tablet Near median
Y-FIX Cefixime 400 mg Capsule 5's 047447 PKR 536.61 PKR 107.32/capsule Near median
Y-FIX Cefixime 100 mg/5 mL Dry suspension 30ml 047448 PKR 299.46 PKR 9.98/mL Near median
Y-FIX DS Cefixime 200 mg/5 mL Dry suspension 30ml 053447 PKR 366.45 PKR 12.22/mL Near median
ZAPROLE Omeprazole 40 mg Injection 1x1 083332 PKR 527.91 PKR 527.91/vial/unit 6% below median
ZAPROLE caps Omeprazole 20 mg Capsule 14's 017587 PKR 236.19 PKR 16.87/capsule 14% below median
ZAPROLE PLUS Omeprazole 40 mg Capsule 2x7's 067188 PKR 485.10 PKR 34.65/capsule Near median
MedInfoBase company-intelligence methodology

This page is generated from MedInfoBase medicine, generic, company, price and DRAP-source records. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.

Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.